1. The clinical significance of sentinel lymph node micrometastasis in breast cancer

   • Neill Patani
   • Kefah Mokbel

   Review 20 April 2008 Pages: 393 - 402

   

2. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis

   • W. L. Lu
   • L. Jansen
   • G. H. De Bock

   Review 18 April 2008 Pages: 403 - 412

   

3. Treatment of metastatic breast cancer: looking towards the future

   • Surabhi Amar
   • Vivek Roy
   • Edith A. Perez

   Review 09 May 2008 Pages: 413 - 422

4. Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis

   • Mehran Habibi
   • Maciej Kmieciak
   • Masoud H. Manjili

   Preclinical Study 20 April 2008 Pages: 423 - 431

   

5. Analysis of the progression of intraductal proliferative lesions in the breast by PCR-based clonal assay

   • Qi Yu
   • Yun Niu
   • YuRong Shi

   Preclinical Study 20 April 2008 Pages: 433 - 440

   

6. Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors

   • Gary M. K. Tse
   • Philip C. W. Lui
   • Puay-Hoon Tan

   Preclinical Study 29 April 2008 Pages: 441 - 448

   

7. Molecular mechanisms of the D327N SHBG protective role on breast cancer development after estrogen exposure

   • Lucia Costantino
   • Maria G. Catalano
   • Nicoletta Fortunati

   Preclinical Study 25 April 2008 Pages: 449 - 456

   

8. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives

   • A-Yong Cao
   • Juan Huang
   • Zhi-Ming Shao

   Preclinical Study 30 April 2008 Pages: 457 - 462

   

9. A pilot genome-wide association study of early-onset breast cancer

   • Muhammad G. Kibriya
   • Farzana Jasmine
   • Habibul Ahsan

   Preclinical Study 08 May 2008 Pages: 463 - 477

   

10. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients

    • Isabel Chirivella
    • Begoña Bermejo
    • Ana Lluch

    Clinical trial Open access 08 May 2008 Pages: 479 - 484

    

11. Analysis of dermatologic events in patients with cancer treated with lapatinib

    • M. E. Lacouture
    • S. M. Laabs
    • K. L. Blackwell

    Clinical trial 04 July 2008 Pages: 485 - 493

    

12. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women

    • J. Murray
    • O. E. Young
    • J. M. Dixon

    Clinical Trial 26 April 2008 Pages: 495 - 501

13. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer

    • Vivien H. C. Bramwell
    • Gordon S. Doig
    • Ann F. Chambers

    Clinical Trial 25 April 2008 Pages: 503 - 511

    

14. The prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer

    • Maysa M. Abu-Khalaf
    • Lyndsay Harris

    Invited Commentary 02 August 2008 Pages: 513 - 515

15. High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome

    • Pamela J. Goodwin
    • Marguerite Ennis
    • Nicky Hood

    Epidemiology 25 April 2008 Pages: 517 - 525

    

16. Time-varying pattern of recurrence risk for Chinese breast cancer patients

    • Wenjin Yin
    • Genhong Di
    • Zhimin Shao

    Epidemiology 19 April 2008 Pages: 527 - 535

    

17. Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effective

    • Marc Schegerin
    • Anna N. A. Tosteson
    • Brian W. Pogue

    Epidemiology 25 April 2008 Pages: 537 - 547

    

18. Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history

    • Megan L. Welsh
    • Diana S. M. Buist
    • Christopher I. Li

    Epidemiology 25 April 2008 Pages: 549 - 558

19. DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study

    • Meng Hua Tao
    • Peter G. Shields
    • Jo L. Freudenheim

    Epidemiology 08 May 2008 Pages: 559 - 568

20. ‘Weighing in’ on screening mammography

    • David Berz
    • William Sikov
    • Sherry Weitzen

    Epidemiology 20 May 2008 Pages: 569 - 574

    

21. Mutations of the MYH gene do not substantially contribute to the risk of breast cancer

    • Mario E. Beiner
    • William W. Zhang
    • Steven A. Narod

    Epidemiology 04 May 2008 Pages: 575 - 578

22. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects

    • Heather-Jane Au
    • Kamran Golmohammadi
    • Philip Jacobs

    Epidemiology 29 April 2008 Pages: 579 - 587

    

23. Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)

    • Sang Gyu Lee
    • Young Geon Jee
    • Jae Hong Seo

    Clinical Trial 25 April 2008 Pages: 589 - 595

    

24. Cost effectiveness, chemotherapy, and the clinician

    • Jennifer J. Griggs
    • Melony E. S. Sorbero

    Invited Commentary 10 August 2008 Pages: 597 - 598

25. Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis

    • Massimiliano Cazzaniga
    • Tarik Gheit
    • Massimo Tommasino

    Brief Report 09 May 2008 Pages: 599 - 605